Cardiff Oncology, Inc. Annual Report Summary: A Deep Dive into 2023 Performance

This summary provides a clear overview of Cardiff Oncology, Inc.'s financial and operational performance for the fiscal year ended December 31, 2023, based on its latest 10-K filing. Cardiff Oncology trades on the Nasdaq stock market under the ticker symbol CRDF.

Business Overview

Cardiff Oncology is a clinical-stage biotechnology company developing precision medicines for cancer. Its primary focus is onvansertib, an oral, first-in-class PLK1 (Polo-like Kinase 1) inhibitor. PLK1 is a protein crucial for cell division and often overexpressed in various cancers. By inhibiting PLK1, onvansertib aims to disrupt cancer cell growth and induce cell death.

The company currently evaluates onvansertib in multiple clinical trials for various cancer types:

• Metastatic Colorectal Cancer (mCRC): A Phase 2 trial (NCT03829410) is ongoing, testing onvansertib in combination with standard chemotherapy (FOLFIRI and bevacizumab) for second-line mCRC patients.
• Acute Myeloid Leukemia (AML): A Phase 2 trial (NCT05534126) assesses onvansertib with decitabine in patients with relapsed/refractory AML.
• Pancreatic Ductal Adenocarcinoma (PDAC): Preclinical studies explore onvansertib's potential in PDAC, with plans for future clinical development.

Cardiff Oncology's strategy centers on advancing onvansertib through late-stage clinical development, exploring its potential in additional cancer types, and seeking strategic partnerships for commercialization.

Financial Performance

As a clinical-stage company, Cardiff Oncology does not yet generate revenue from product sales. It funds its operations through equity financings.

• Net Loss: For the fiscal year ended December 31, 2023, the company reported a net loss of approximately $72.5 million, an increase from $65.1 million in the prior year. This reflects significant investment in research and development.
• Research & Development (R&D) Expenses: R&D expenses totaled $61.8 million for the year, primarily due to clinical trial costs for onvansertib, manufacturing activities, and personnel expenses.
• General & Administrative (G&A) Expenses: G&A expenses were $15.2 million for the same period, mainly related to personnel, professional services, and other corporate overhead.

Financial Health

• Cash Position: On December 31, 2023, Cardiff Oncology held cash, cash equivalents, and marketable securities totaling approximately $115.7 million.
• Debt: The company reported no significant long-term debt.
• Liquidity & Cash Runway: Based on current operating expenses and projected R&D spend, the company expects its existing cash resources can fund operations into the second quarter of 2025. However, the company explicitly states it must raise substantial additional capital to fund operations beyond this period.

Management Discussion (MD&A Highlights)

Management highlighted the company's focus on advancing its lead product candidate, onvansertib, through ongoing clinical trials. The increase in net loss and R&D expenses for the fiscal year ended December 31, 2023, resulted from increased clinical trial activity, manufacturing scale-up efforts, and related personnel costs associated with onvansertib's development across its various indications. Management emphasized the critical need for additional capital to support future operations and clinical development beyond the current cash runway. Its financial strategy focuses on managing cash burn while advancing clinical programs and exploring financing opportunities.

Future Outlook

Cardiff Oncology's future outlook depends on onvansertib's successful progression through clinical development. Key data readouts from the Phase 2 mCRC trial, anticipated in mid-2024, represent significant milestones. The company plans to continue exploring onvansertib's potential in additional cancer types, such as PDAC, and to advance its preclinical programs. Its strategy includes potentially seeking strategic partnerships for onvansertib's commercialization, should it achieve regulatory approval. Securing additional funding will be critical to sustaining operations and executing these development plans beyond the second quarter of 2025.

Competitive Position

The oncology market is highly competitive and rapidly evolving, marked by intense research and development from numerous pharmaceutical and biotechnology companies. Cardiff Oncology operates in this landscape, competing with established pharmaceutical companies that have significant resources, as well as other clinical-stage biotech firms developing novel cancer therapies. Competitors include companies developing standard-of-care treatments for mCRC, AML, and PDAC, alongside those with investigational drugs targeting similar pathways or indications. Factors like product efficacy, safety, convenience, cost, and market access influence the competitive landscape. Cardiff Oncology's competitive success will depend on onvansertib's clinical profile, its intellectual property protection, and the company's ability to navigate regulatory pathways and secure market adoption.

Risk Factors

Investing in Cardiff Oncology involves significant risks inherent to clinical-stage biotechnology companies:

• Clinical Development & Regulatory Risk: Cardiff Oncology's success depends almost entirely on onvansertib's successful development, regulatory approval, and commercialization. Clinical trials are lengthy, expensive, and have a high rate of failure. Onvansertib may not demonstrate sufficient efficacy or safety to gain approval from regulatory bodies like the FDA, nor may it be commercially viable even if approved. Delays or failures in clinical trials could severely impact the company's prospects.
• Financial Viability & Need for Additional Capital: The company has a history of significant net losses and expects to incur substantial expenses for the foreseeable future. Developing new drugs is capital-intensive. Cardiff Oncology explicitly states it must raise substantial additional capital to fund operations beyond its current cash runway. Failing to secure adequate funding—through equity offerings (which would dilute existing shareholders), debt financing, or strategic partnerships—could force the company to delay, scale back, or even cease its development programs.
• Intellectual Property Risk: The company relies on its ability to protect its intellectual property, primarily through patents covering onvansertib. Patent protection may prove insufficient, and competitors may develop similar or superior products or challenge Cardiff Oncology's patents.
• Reliance on Third Parties: Cardiff Oncology relies heavily on contract research organizations (CROs) to conduct its clinical trials and contract manufacturing organizations (CMOs) for onvansertib's supply. Failure or underperformance by these third parties could significantly impact development timelines and costs.
• Competition: The oncology market is highly competitive, with numerous pharmaceutical and biotechnology companies developing treatments for mCRC, AML, and other cancers. Onvansertib faces intense competition from existing therapies and new treatments in development.
• Market Acceptance: Even with regulatory approval, broad market acceptance by physicians, patients, or payers is not guaranteed, which could limit commercial success.

In summary, Cardiff Oncology presents a high-risk, high-reward investment opportunity. Its future hinges on onvansertib's successful and timely progression through clinical trials and the company's ability to secure ongoing financing.